CIK 0001842295 · Non-accelerated filer<br>Emerging growth company
Maze Therapeutics, Inc.
Sign in to watch- Ticker
- MAZE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 6508505070
- Business address
- 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,785,701
- in 13 filings, $4.6M under 10b5-1 plans
Net −$5,785,701. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-02 | Bernstein Harold President, R&D & CMO | Sale 10b5-1 | −5,936 | $46.37 | $275K | 100 |
| 2026-02-02 | Bernstein Harold President, R&D & CMO | Sale 10b5-1 | −100 | $47.23 | $5K | 0 |
| 2026-02-02 | Bernstein Harold President, R&D & CMO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −15,000 | 297,407 | ||
| 2026-01-29 | Dandekar Atul CSBO | Option exercise 10b5-1 | +7,500 | $10.42 | $78K | 18,003 |
| 2026-01-29 | Dandekar Atul CSBO | Sale 10b5-1 | −1,200 | $43.18 | $52K | 16,803 |
| 2026-01-29 | Dandekar Atul CSBO | Sale 10b5-1 | −3,500 | $44.04 | $154K | 13,303 |
| 2026-01-29 | Dandekar Atul CSBO | Sale 10b5-1 | −2,800 | $45.01 | $126K | 10,503 |
| 2026-01-29 | Dandekar Atul CSBO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,500 | 66,643 | ||
| 2026-01-22 | Bachrodt Amy SVP, Finance | Option exercise 10b5-1 | +2,497 | $10.42 | $26K | 15,462 |
| 2026-01-22 | Bachrodt Amy SVP, Finance | Option exercise 10b5-1 | +2,503 | $10.42 | $26K | 17,965 |
| 2026-01-22 | Bachrodt Amy SVP, Finance | Sale 10b5-1 | −5,000 | $45.52 | $228K | 12,965 |
| 2026-01-22 | Bachrodt Amy SVP, Finance | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,497 | 486 | ||
| 2026-01-22 | Bachrodt Amy SVP, Finance | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,503 | 7,869 | ||
| 2026-01-07 | Bernstein Harold President, R&D & CMO | Option exercise 10b5-1 | +25,156 | $10.42 | $262K | 25,156 |
| 2026-01-07 | Bernstein Harold President, R&D & CMO | Sale 10b5-1 | −25,156 | $40.20 | $1.0M | 0 |
| 2026-01-07 | Bernstein Harold President, R&D & CMO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −25,156 | 312,407 | ||
| 2026-01-07 | Sohn Catherine A. Director | Option exercise | +20,744 | $10.42 | $216K | 20,744 |
| 2026-01-07 | Sohn Catherine A. Director | Option exercise | +2,895 | $10.42 | $30K | 23,639 |
| 2026-01-07 | Sohn Catherine A. Director | Option exercise | +3,281 | $10.42 | $34K | 26,920 |
| 2026-01-07 | Sohn Catherine A. Director | Sale | −26,920 | $39.11 | $1.1M | 0 |
Page 9 of 14 · 267 trades